The hormone insulin coordinates the catabolism of nutrients by protein phosphorylation. Phosphoproteomic analysis identified insulin-responsive phosphorylation of the Glu/Asp transporter SLC1A3/EAAT1 in adipocytes. The role of SLC1A3 in adipocytes is not well-understood. We show that SLC1A3 is localised to the plasma membrane and the major regulator of acidic amino acid uptake in adipocytes. However, its localisation and activity were unaffected by insulin or mutation of the insulin-regulated phosphosite. The latter was also observed using a heterologous expression system in Xenopus laevis oocytes. Thus, SLC1A3 maintains a constant import of acidic amino acids independently of nutritional status in adipocytes.
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The peptide hormone insulin acts on several tissues to stimulate the uptake and catabolism of glucose. This is regulated in concert with the processing of other substrates, including the transport of amino acids (e.g. [1] [2] [3] ). In adipocytes, this ensures both glucose and amino acids are co-utilised to support de novo lipogenesis [4] . The coordinated metabolic response by insulin is mediated by dynamic phosphorylation cascades [5] , which we previously examined by phosphoproteomics in adipocytes [6] . This highlighted that numerous metabolic proteins are phosphorylated in response to insulin [6] , suggesting that insulin signalling interfaces with adipocyte metabolic processes more extensively than by simply promoting glucose transport. For instance, the protein 'solute carrier family 1 member 3' (SLC1A3/EAAT1) contains a phosphorylation site that is highly responsive to insulin ( Fig. 1) .
SLC1A3 belongs to the excitatory amino acid transporter (EAAT) family, which bears conserved homology to glutamate transporters in archaea and bacteria [7] . This transporter mediates the uptake of acidic amino acids (Asp/Glu), coupled with the import of three Na + ions and one H + , the export of K + , and also has an uncoupled Cl À conductance [7] . Consequently, a substantial body of research has elucidated Abbreviations 2DOG, 2-deoxyglucose; D-Asp, D-aspartate; HDM, high-density microsomes; LDM, low-density microsomes; PM, plasma membrane; SLC1A3, solute carrier family 1 member 3; Y523, tyrosine residue 523.
the role that SLC1A3 plays in the central nervous system, clearing excess glutamate from synapses [7] . Long-term treatments with insulin and other growth factor stimuli have been shown to modulate SLC1A3 expression and activity [8] [9] [10] , but little is known about whether SLC1A3 activity is acutely regulated (seconds to minutes) by insulin signalling or its role in metabolic tissues. The tissue expression of SLC1A3 is rather restricted, for instance being found in brain, epithelial and adipose, but not liver tissue [11] . Within these tissues, SLC1A3 may play distinct roles as it is reportedly targeted to different locations between cell types. For example, it is situated on the plasma membrane (PM) of astrocytes, where it serves to import extracellular Glu/Asp [12] and forms a macromolecular complex with metabolic enzymes and mitochondria [13] . However, it localises to mitochondria of cardiomyocytes, where it contributes to the malate-aspartate shuttle [14] . The role of SLC1A3 in adipocytes has not been thoroughly characterised.
Here, we aimed to determine the localisation of SLC1A3 in adipocytes and the functional consequences of its insulin-regulated phosphorylation, to assess whether SLC1A3 represents a novel site of insulin action. Biochemical and microscopy techniques demonstrated that this transporter is PM-localised. SLC1A3 appears to be responsible for a majority of the acidic amino acid uptake in adipocytes. However, a combination of genetic and pharmacological techniques showed that neither the activity nor localisation of SLC1A3 is influenced by insulin, suggesting that acidic amino acid transport through SLC1A3 occurs independently of insulin status. Fig. 1 . Insulin stimulates rapid phosphorylation of SLC1A3 in adipocytes. (A) 3T3-L1 adipocytes were serum-starved and treated with insulin (100 nM) for varying time periods. Phosphorylation at residue Y523 of SLC1A3 was measured using mass spectrometry. Data obtained from [6] . Data presented as mean AE SEM, from three separate biological samples per time-point. (B) The SLC1A3 protein sequences from the following species were aligned using Clustal Omega [39] : human (UniProt ID P43003), mouse (UniProt ID P56564), rat (UniProt ID P24942), dog (UniProt ID Q9N280), cow (UniProt ID P46411), chicken (UniProt ID E1C7B5), Xenopus (UniProt ID F7CSQ4), zebrafish (UniProt ID Q7ZUB7). Y523 is highlighted in black. '*', fully conserved; ':', conservation between strongly similar residues; '.', conservation between weakly similar residues, as defined in [39] . (C) Membrane topology of SLC1A3 (figure reproduced from reference [40] ). Transmembrane domains are numbered separately from the hairpin (HP) loops. Y523 is indicated by the star.
Materials and methods

Cell culture
3T3-L1 fibroblasts were passaged and differentiated into adipocytes as described previously [15] , using Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) FBS and 2 mM GlutaMAX (Life Technologies, Scoresby, Vic, Australia; Media A). Adipocytes were used between days 9 and 12 after the initiation of differentiation. In experiments involving insulin treatment, cells were washed with phosphate-buffered saline (PBS) and incubated in DMEM supplemented with 0.2% (w/v) BSA and 2 mM GlutaMAX (Media B) for 1.5 h prior to the experiment.
Molecular cloning and mutagenesis of SLC1A3
For adipocyte experiments, the SLC1A3 gene was cloned from CMV-hEAAT1 (a gift from S. Amara, Addgene plasmid #32813; Cambridge, MA, USA) into pcDNA3.1 and subsequently into pBABE-puro, and simultaneously tagged with an N-terminal FLAG tag (DYKDDDDK), using Gibson assembly cloning [16] . For oocyte experiments, SLC1A3 cDNA was subcloned into the plasmid oocyte transcription vector (pOTV). Y523F mutants were generated using either PCR-based mutagenesis as described previously [17] or the Q5 Site-Directed Mutagenesis kit (New England Biolabs, distributed by GeneSearch Pty Ltd (Arundel, Qld, Australia)). Oligonucleotide primers used in these experiments were synthesised by Sigma-Aldrich (Castle Hill, NSW, Australia), and sequences are available upon request. Constructs and pOTV cDNA products were confirmed by sequencing, via the Australian Genome Research Facility (Sydney, Australia).
Cell transfection
Stable overexpression by retroviral transduction
To generate cells stably overexpressing SLC1A3, HEK293 PLAT-E cells were used to generate retrovirus from pBABE puro (empty vector control) or pBABE-SLC1A3-NFLAG (both wild-type and Y523F) [18] . These retroviruses were used to infect 3T3-L1 fibroblasts [19] , which were then selected for and maintained in Media A supplemented with puromycin (2 lgÁmL À1 ), prior to differentiation.
Transient overexpression by electroporation
Seven days postdifferentiation, adipocytes were trypsinised and electroporated as described previously [15] , using 15 lg of plasmid containing wild-type or Y523F-mutant SLC1A3 (in the pcDNA3.1 backbone, N-terminally FLAG tagged).
Following electroporation, cells were seeded onto Matrigel (Corning, distributed by Sigma-Aldrich)-coated coverslips, and cultured in Media A. Cells were assayed 72 h following electroporation.
Subcellular fractionation
Fractions enriched for PM, low-density microsomes (LDM), high-density microsomes (HDM), mitochondria/ nuclei, and cytosol were obtained from differential centrifugation as described previously [15] . 3T3-L1 adipocytes were washed with ice-cold PBS, harvested in ice-cold HES-I buffer (10 mM HEPES, pH 7.4, 1 mM EDTA, 250 mM sucrose, protease inhibitors), and subsequent steps were carried out at 4°C. Cells were homogenised by 12 strokes of a Dounce homogeniser prior to centrifugation at 500 g for 10 min to pellet unbroken cells. The resulting supernate was centrifuged at 13 550 g for 12 min to pellet the PM and mitochondria/nuclei. The resulting supernate consisted of cytosol and microsomes. The supernate was then centrifuged at 21 170 g for 17 min to pellet the HDM fraction.
The supernate was centrifuged again at 235 200 g for 75 min to obtain a cytosol fraction (supernate) and LDM fraction (pellet). The PM/mitochondria/nuclei pellet was resuspended/washed in HES-I and recentrifuged at 13 550 g for 12 min. The pellet was resuspended again in HES-I and layered over a high sucrose HES buffer (1.12 M sucrose, 0.05 mM EDTA, 10 mM HEPES, pH 7.4) and centrifuged at 111 160 g for 60 min in a swing-out rotor. The pellet was the mitochondria/nuclei fraction. The PM fraction was collected above the sucrose layer, and centrifuged again at 13 550 g for 12 min to achieve a PM pellet. All fractions were resuspended in HES-I. Protein concentration for each fraction was performed using the BCA assay (Thermo Scientific, Scoresby, Vic., Australia).
Immunoblotting
Ten micrograms of 3T3-L1 protein or 20 lg of oocyte protein were resolved by SDS/PAGE, transferred to PVDF membranes and immunoblotted as described previously [15] . Antibodies detecting SLC1A3 (clone D44E2, catalog #5684), Akt (clone 11E7, catalog #4685) and Ser(P)-473 Akt (clone D9E, catalog #4060) were obtained from Cell Signaling Technology (distributed by GeneSearch Pty Ltd).
The antibody detecting 14-3-3 (clone K19, catalog #sc-629) was obtained from Santa Cruz Biotechnology (distributed by VWR International, Murarrie, Qld, Australia). Antibodies against GLUT4 were generated in-house. Antibody to the plasma membrane marker Caveolin-1 was from BD Transduction Laboratories (distributed by BD Biosciences, North Ryde, NSW, Australia) (catalog #610407) and the antibody cocktail to mitochondrial oxidative phosphorylation complex subunits from Thermo Scientific (catalog #45-8099).
Immunofluorescence microscopy
Following treatment, cells were washed, fixed and immunostained as described previously [15] , using rabbit anti-FLAG primary antibody (Sigma-Aldrich) and anti-rabbit Alexa-488-conjugated secondary antibody (Life Technologies). 4,6 0 -Diamidino-2-phenylindole dihydrochloride (Life Technologies) was used to visualise nuclei. Optical sections were obtained using the Leica TCS DM6000 SP8 confocal laserscanning microscope using a HC PL APO 639/1.20 W CORR CS2 objective. Images were acquired using Leica LCS software (Leica Microsystems, Macquarie Park, NSW, Australia). All images were processed using Fiji [20] . H]-Asp (PerkinElmer Life Sciences, Glen Waverley, Vic., Australia), made up to 5 lM total with unlabelled D-Asp, unless otherwise specified in the figure legends. Following three rapid washes in ice-cold PBS, cells were solubilised in 1% (w/v) Triton X-100 in PBS on a shaker for 1 h and assessed for radioactivity by scintillation counting using a b-scintillation counter. All data were normalised to protein content. This assay is linear for the first 5 min of D-Asp uptake (data not shown).
Oocyte experiments
Harvesting and preparing oocytes
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Xenopus laevis frogs were obtained from NASCO (Wisconsin, USA). Stage V oocytes were harvested from X. laevis as previously described [22] with all surgical procedures in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
cRNA injection
Wild-type (WT) SLC1A3 and the Y523F mutant cDNAs were linearised with SpeI (New England Biolabs, distributed by GeneSearch Pty Ltd) and transcribed to cRNA by T7 RNA polymerase using the mMessage mMachine kit (Ambion, Austin, TX, USA). Defoliculated stage V oocytes were injected with 4.6 ng of cRNA (Drummond Nanoject, Drummond Scientific Co, Broomall, PA, USA) and subsequently incubated at 16-18°C in standard frog Ringer's solution (ND96: 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES, pH 7.5) supplemented with 50 lgÁmL À1 gentamycin, 2.5 mM sodium pyruvate, 50 lgÁmL À1 tetracyclin and 0.5 mM theophylline.
Electrophysiology
Around 2-4 days after injections, currents were recorded using the two-electrode voltage clamp technique with a Geneclamp 500 amplifier (Axon Instruments, Foster City, CA, USA) interfaced with a PowerLab 2/20 chart recorder (ADInstruments, Bella Vista, NSW, Australia) used in conjunction with Chart software (ADInstruments; Axon Instruments). Glutamate concentration responses were measured on both WT SLC1A3 and the Y523F mutant transporters before and after a 15-min incubation with 120 lM Insulin (in the presence of 0.5% (w/v) BSA) and a 2-min washout period. Background currents were eliminated by subtracting currents in the absence of substrate from substrate-elicited currents at À60 mV. Raw currents were normalised to the preinsulin I max .
Current measurements at À60 mV (I) were fitted by least squares to a derivation of the Michaelis-Menten equation:
, where I max is the maximal current, [S] is the substrate concentration, and K 0.5 is the concentration of substrate required to produce the half maximal current.
Extraction of protein
Following insulin stimulation, oocytes were lysed in PBS supplemented with 1% (w/v) SDS, protease inhibitors (Roche Applied Science, North Ryde, NSW, Australia), 1 mM sodium pyrophosphate, 2 mM sodium orthovanadate and 10 mM sodium fluoride. Cell lysates were sonicated for 10 s and centrifuged at room temperature at 16 000 g. After removal of the lipid layer, the protein concentration of the supernatant was determined by BCA assay (Thermo Scientific).
Results and Discussion
We previously conducted a phosphoproteomics screen in 3T3-L1 adipocytes treated with insulin [6] . Given the importance of insulin signalling in the regulation of metabolism, we were interested in identifying insulin-regulated phosphoproteins that regulate metabolic processes. One of the most insulin-sensitive phosphosites identified from this study was tyrosine residue 523 (Y523) on SLC1A3 (Fig. 1A) . Phosphorylation at this site increased~20-fold within 1 min of insulin stimulation and remained high throughout the time-course. These phosphorylation kinetics are similar to that of T642 on Rab-GAP AS160 [6] , which initiates the translocation of GLUT4 to the PM, leading to the ) and K m 's (in lM D-Asp) were calculated from (B), presented as mean AE SEM, from three separate experiments. There was no significant difference between treatments for either V max or K m (P > 0.05, paired t-test). (D-F) 3T3-L1 adipocytes stably overexpressing empty vector (EV), wild-type SLC1A3 (WT) or phosphomutant SLC1A3 (Y523F) were generated, and 2DOG uptake (D) or D-Asp uptake in the absence (E) or presence (F) of 25 lM UCPH101 was measured. Data presented as mean AE SEM, from at least three separate experiments, each performed with duplicate wells per condition.
acute glucose uptake that is well-known to be stimulated by insulin [23] . Thus, we hypothesised that this site on SLC1A3 may also play an important role in the metabolic response to insulin.
Interestingly, Y523 and its surrounding residues are widely conserved across the animal kingdom (Fig. 1B) . Furthermore, phosphorylation at this site has been detected in several other phosphoproteomic studies [24] [25] [26] , but its functional consequence has not yet been investigated. This residue is located in the cytosolic C-terminal tail (Fig. 1C) . The C terminus of other glutamate transporters plays a role in transporter localisation [27] [28] [29] and activity [27] . Its surrounding residues (YQLI) resemble an endocytic-sorting motif [30, 31] -interestingly, mutating the GLUT4-trafficking motif from FQQI to YQQI promoted internal retention of GLUT4 [32] . Thus, modification at this motif may alter the localisation of SLC1A3. Furthermore, it has been previously reported in glial cells that IGF-1 acts through the PI3K kinase signalling pathway to increase surface SLC1A3 [33] and PDGF acts via Akt kinase to promote rapid translocation of EAAC1 (an SLC1A3 homolog) to the cell surface [34] . Thus, we hypothesised that insulin may act via phosphorylation of Y523 to influence the localisation and/or activity of SLC1A3 in adipocytes.
SLC1A3 has been reported to be localised to either the PM [12] or mitochondria [14] . We determined the localisation of SLC1A3 in adipocytes using two complementary approaches. First, subcellular fractionation using differential centrifugation showed an enrichment of endogenous SLC1A3 in the PM-enriched fraction and we did not detect SLC1A3 in the mitochondrially enriched fraction (Fig. 2A) . This distribution did not change with insulin stimulation ( Fig. 2A,B ; P~0.4 with paired t-test). In contrast, the localisation of the insulin-responsive glucose transporter (GLUT4) shifted from the LDM fraction to the PM fraction in response to insulin treatment. Next, we electroporated adipocytes with either wild-type SLC1A3 or a phosphomutant (Y523F) and performed immunofluorescence. This revealed a predominant PM staining, regardless of the phosphomutation status or insulin stimulation (Fig. 2C) . Thus, SLC1A3 is localised to the PM in adipocytes, independently of insulin treatment.
We next tested the effects of insulin on SLC1A3 activity in adipocytes by measuring the uptake of a nonmetabolisable substrate, D-Asp. Treatment with 100 nM insulin, sufficient to increase the uptake of the glucose analogue 2-deoxyglucose (Fig. 3A) , had no effect on the kinetics of D-Asp uptake (Fig. 3B,C) . We tested this further using adipocytes that were stably overexpressing either wild-type or phosphomutant SLC1A3. This overexpression did not interfere with the insulin sensitivity of the cells (Fig. 3D ), but increased D-Asp uptake compared to the empty vector controls by~2.5 fold (Fig. 3E) . However, neither insulin nor the mutation of Y523 affected D-Asp uptake (Fig. 3E) . To determine if SLC1A3 is the predominant transporter that regulates D-Asp uptake in adipocytes, we next used UCPH101, an SLC1A3-selective nontransportable inhibitor [35] . UCPH101 inhibited D-Asp uptake by 80% in control (empty vector, EV; Fig. 3F ) and untransfected adipocytes (data not shown), highlighting that SLC1A3 is the dominant transporter for acidic amino acids in adipocytes. Cells overexpressing SLC1A3 were equally sensitive to UCPH101, regardless of insulin treatment or phosphomutation (Fig. 3F) , reinforcing the notion that insulin did not influence SLC1A3 activity.
To rule out the possibility of adipocyte-specific factors masking the effects of insulin on SLC1A3, we examined SLC1A3 activity in oocytes transfected with SLC1A3. Insulin stimulated the phosphorylation of Akt in oocytes, demonstrating that the insulin signalling pathway is intact in this system (Fig. 4A) . Nevertheless, neither insulin treatment nor the phosphomutant had an effect on SLC1A3 activity, as measured by uptake of its substrate glutamate (Fig. 4B-C) . We observed similar results when BSA was excluded from the assay media (data not shown).
In summary, SLC1A3 is localised to the PM in adipocytes (Fig. 2) , suggesting it contributes to the majority of acidic amino acid import into adipocytes (Fig. 3) . It is acutely and robustly phosphorylated in response to insulin (Fig. 1 ), but this phosphorylation does not affect the localisation (Fig. 2) or activity ( Figs 3 and 4) of the transporter. Previous studies have shown that growth factor signalling can influence the transcriptional [8, 9] and post-transcriptional [10] control of SLC1A3 levels. We have previously shown that the insulin exposure used here can activate mTOR signalling [6] , which would elevate global protein synthesis and thus could augment SLC1A3 levels. However, insulin did not influence endogenous SLC1A3 protein levels ( Fig. 2A ) nor transporter activity (Fig. 3) , thus unlikely regulating SLC1A3 expression within the 20-min time-frame of our experiments. It will be of interest to interrogate whether more chronic insulin stimulation can influence SLC1A3 abundance in adipocytes via transcriptional, translational or post-translational mechanisms.
Furthermore, our previous phosphoproteomics study identified additional phosphorylation sites in SLC1A3 [6] . Although these other sites were not found to be insulin-regulated, this emphasises that the role that phosphorylation plays in regulating SLC1A3 biology is yet to be fully elucidated. In addition, although insulin-dependent phosphorylation does not influence SLC1A3 localisation or activity, this does not exclude the possibility that the phosphosite Y523 plays another function such as regulating protein-protein interactions. For instance, the C terminus of a related glutamate transporter, GLT1b/EAAT2, interacts with PICK1 to modulate the response of GLT1b to PKC [36] , linking the transporter to kinase activity. Interestingly, Gab1 also possesses the same YQLI motif as SLC1A3, which was hypothesised to enable Gab1 to bind the SH2 domain of Shc in B-cell antigen receptor engagement [37] . However, the motif prediction algorithm Scan-Site [38] could not predict any putative interactors for this phosphotyrosine site in either human or mouse SLC1A3 (data not shown). Although the functional consequence of this phosphorylation event remains to be elucidated, phosphorylation at Y532 does not modify the location or activity of SLC1A3, such that acidic amino acid transport into adipocytes occurs at similar rates in the presence or absence of insulin.
